Drug Trial Radar · NCT06953934
A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
May 4, 2026
Primary completion
Sep 14, 2026
Study completion Sep 14, 2026
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- May 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objective of this study is to assess the safety and tolerability of ABBV-932 in healthy adult male participants.
Conditions
- Healthy Volunteer
Interventions
ABBV-932Drug
Oral Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Plasma Concentration (Cmax) of ABBV-932Time frame: Up to approximately 86 days
- Time to Cmax (Tmax) of ABBV-932Time frame: Up to approximately 86 days
- Terminal phase elimination rate constant (λz) of ABBV-932Time frame: Up to approximately 86 days
- Terminal Phase Elimination Half-Life (t1/2) of ABBV-932Time frame: Up to approximately 86 days
- Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-932Time frame: Up to approximately 86 days
- Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-932Time frame: Up to approximately 86 days
- Number of Participants Experiencing Adverse EventsTime frame: Up to approximately 103 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ICON Clinical Research /ID# 270490
Groningen, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.